# A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

> **NCT07075640** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AG-236
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07075640
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2026-02-11
- **Final completion:** 2026-08-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075640, "A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07075640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*